In recent years, incretin-based therapies, particularly GLP-1 receptor agonists and DPP-IV inhibitors, have emerged as a focal point in diabetes treatment research owing to their capacity to prolong endogenous GLP-1 activity, effectively control postprandial glucose levels, and demonstrate favorable safety and tolerability profiles [2]. Here, GLP1R is linked to diabetes mellitus.